Climb Bio, Inc. (NASDAQ:CLYM – Free Report) – Research analysts at Leerink Partnrs issued their Q4 2024 EPS estimates for Climb Bio in a research report issued on Monday, December 2nd. Leerink Partnrs analyst T. Smith forecasts that the company will post earnings per share of ($0.15) for the quarter. Leerink Partnrs currently has a “Strong-Buy” rating on the stock. Leerink Partnrs also issued estimates for Climb Bio’s Q1 2025 earnings at ($0.15) EPS, Q2 2025 earnings at ($0.16) EPS, Q3 2025 earnings at ($0.16) EPS, Q4 2025 earnings at ($0.17) EPS, FY2027 earnings at ($1.12) EPS and FY2028 earnings at ($1.74) EPS.
Separately, Leerink Partners started coverage on Climb Bio in a report on Monday. They set an “outperform” rating and a $10.00 price target for the company.
Climb Bio Stock Down 3.4 %
CLYM stock opened at $3.15 on Tuesday. Climb Bio has a twelve month low of $2.35 and a twelve month high of $11.55.
About Climb Bio
Climb Bio Inc is a clinical-stage biotechnology company developing therapeutics for patients with immune-mediated diseases. The Company’s lead product candidate, budoprutug, is an anti-CD19 monoclonal antibody which has demonstrated B-cell depletion and has potential to treat a broad range of B-cell mediated diseases.
Featured Articles
- Five stocks we like better than Climb Bio
- What Does a Gap Up Mean in Stocks? How to Play the Gap
- Beyond NVIDIA: Top 5 Semiconductor Stocks to Watch for 2025
- Low PE Growth Stocks: Unlocking Investment Opportunities
- Netflix Is On Track To Hit $1,000 By Christmas
- How to Invest in Blue Chip Stocks
- UMAC Stock Climbs Amid Trump Jr. Appointment and Meme Stock Hype
Receive News & Ratings for Climb Bio Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Climb Bio and related companies with MarketBeat.com's FREE daily email newsletter.
